Skip to content

Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.

Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.

Published on

Stanford scientists have dug up a defect at the heart of rheumatoid arthritis: a faulty "anchor" that should be tethering a key molecule to the spot inside immune cells where it has to be in order to do its job.  It seems this defect can be reversed with a not yet commercially available small-molecule drug.

Stanford scientists have dug up a defect at the heart of rheumatoid arthritis: a faulty "anchor" that should be tethering a key molecule to the spot inside immune cells where it has to be in order to do its job.  It seems this defect can be reversed with a not yet commercially available small-molecule drug.

Published on

In a video, Stanford Children's Health's Healthier, Happier Lives Blog introduces a patient with celiac disease and discusses the symptoms, diagnosis and treatment of the autoimmune disorder.

In a video, Stanford Children's Health's Healthier, Happier Lives Blog introduces a patient with celiac disease and discusses the symptoms, diagnosis and treatment of the autoimmune disorder.

Rheumatoid arthritis and coronary artery disease share a common culprit: an important type of immune cell, called a macrophage, that has gone haywire. Stanford investigators have zeroed in on a molecular defect in macrophages' metabolic process that drives both disorders.

Rheumatoid arthritis and coronary artery disease share a common culprit: an important type of immune cell, called a macrophage, that has gone haywire. Stanford investigators have zeroed in on a molecular defect in macrophages' metabolic process that drives both disorders.